Author response to Cunha et al

The need to identify biomarkers to predict immunotherapy response for rare cancers has been long overdue. We aimed to study this in our paper, ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. In this response to the Letter to the Editor by Cunha et a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2021
Предметы:
Commentary
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317086/
https://ncbi.nlm.nih.gov/pubmed/34315823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003299
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы